Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) have been given a consensus rating of “Buy” by the six research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $40.80.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research raised shares of Calliditas Therapeutics AB (publ) from a “sell” rating to a “hold” rating in a report on Tuesday, May 11th. HC Wainwright assumed coverage on shares of Calliditas Therapeutics AB (publ) in a report on Friday, February 26th. They issued a “buy” rating and a $52.00 target price on the stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in Calliditas Therapeutics AB (publ) in the 1st quarter valued at about $264,000. Tudor Investment Corp Et Al acquired a new position in Calliditas Therapeutics AB (publ) in the 1st quarter valued at about $380,000. Endurant Capital Management LP acquired a new position in Calliditas Therapeutics AB (publ) in the 1st quarter valued at about $3,923,000. Finally, Hillhouse Capital Advisors LTD. grew its stake in Calliditas Therapeutics AB (publ) by 199.3% in the 4th quarter. Hillhouse Capital Advisors LTD. now owns 1,047,687 shares of the company’s stock valued at $35,611,000 after buying an additional 697,687 shares during the last quarter. Institutional investors and hedge funds own 9.35% of the company’s stock.

NASDAQ:CALT traded up $1.33 on Friday, hitting $31.01. 110 shares of the company’s stock were exchanged, compared to its average volume of 34,796. The business has a 50-day simple moving average of $28.43. Calliditas Therapeutics AB has a 52 week low of $19.00 and a 52 week high of $38.00. The stock has a market capitalization of $774.35 million and a P/E ratio of -13.37.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last issued its quarterly earnings results on Monday, May 17th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.17). On average, analysts predict that Calliditas Therapeutics AB will post -2.74 EPS for the current year.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. The company's lead product candidate is Nefecon, a oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease IgA nephropathy.

See Also: What is the Current Ratio?

Analyst Recommendations for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.